ClinicalTrials.gg
RecruitingNCT07092423SEMINARUpdated Apr 30, 2026

Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury.

An interventional study of Semi-elemental formula and Standard formula in Traumatic Brain Injury, Neurocritical Care and Enteral Feeding Intolerance, sponsored by Tang-Du Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Tang-Du Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.

Planned enrollment
10th of 26
100 · median 83
Started
2025
with 6 others
No phase
18 of 60
8 open now
Primary completion
2026-11
later than 15 of 29 live
Registered
52nd of 60
by date
Lead sponsor
6 of 60
Tang-Du Hospital

Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 15 of the 29 other live ones, and was the 52nd registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Brain Injuries, Traumatic with a site in China, or all of them as a file.
02

Study summary

Study Objective This clinical trial primarily aims to investigate whether semi-elemental enteral nutrition (SEN) improves gastrointestinal tolerance in patients with severe traumatic brain injury (TBI) and to evaluate its impact on clinical outcomes. The safety profile of SEN will also be assessed.

Key Research Questions Does SEN reduce the incidence of acute gastrointestinal injury (AGI) in severe TBI patients?

Study Design

Participants will be randomized 1:1 into either:

Intervention group: Receives SEN initiated within 48 hours post-injury and continued for ≥7 days.

Control group: Receives standard enteral nutrition over the same period.

Read the detailed description

Background:

Patients with traumatic brain injury (TBI) frequently exhibit gastrointestinal dysfunction secondary to central nervous system impairment. This dysregulation impairs nutrient absorption, exacerbates systemic inflammation, and compromises clinical recovery trajectories. Emerging evidence suggests that semi-elemental enteral nutrition (SEN)-featuring hydrolyzed macronutrients with low-osmolality formulations-may mitigate these sequelae by reducing digestive burden and enhancing mucosal healing. However, robust clinical evidence supporting its superiority over standard enteral feeding in severe TBI populations remains limited.

Objectives:

Primary Objective:

To evaluate the efficacy of semi-elemental enteral nutrition (SEN) in improving gastrointestinal tolerance during the acute phase (first 7 days post-injury) in patients with severe traumatic brain injury (TBI).

Secondary Objectives:

  1. To assess gastrointestinal complications within 7 days of enteral nutrition initiation, including:

    Incidence of diarrhea and diarrhea-free days Incidence of constipation Incidence of vomiting Incidence of gastroparesis Incidence of abdominal distension Time to first onset of gastrointestinal intolerance symptoms Duration of gastrointestinal intolerance symptoms

  2. To evaluate clinical outcomes:

    Hospitalization duration (total and ICU-specific) 6-month mortality and functional recovery

  3. To determine safety profiles:

Infection rates Pneumonia incidence Other adverse events

Study Design:

A multicenter, randomized, double-blind, parallel-group exploratery trial will be conducted. 100 severe TBI patients will be allocated 1:1 to intervention (SEN formula) or control (standard formula) arms within 48 hours of injury.

03

Conditions studied

  • Traumatic Brain Injury
  • Neurocritical Care
  • Enteral Feeding Intolerance

Keywords

  • Traumatic Brain Injury
  • Enteral Nutrition
  • Gastrointestinal Intolerance
  • Semi-elemental Formula
  • Neurocritical Care
  • Prognosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-75 years;
  • Clinically diagnosed with closed traumatic brain injury;
  • Glasgow Coma Scale (GCS) score ≤ 8;
  • Ability to initiate enteral nutrition within 48 hours post-injury;
  • Expected need for enteral nutrition support ≥3 days based on clinical assessment (Nutritional Risk Screening 2002 [NRS2002] score ≥3).

Exclusion criteria

Exclusion Criteria:

  • GCS=3 with bilateral fixed and dilated pupils;
  • Hemodynamic instability or respiratory failure: mean arterial pressure \<70mmHg, PaO2/FiO2\<150, PaCO2\<30 mmHg or >45 mmHg, or lactate >5 mmol/l;
  • to both nasogastric and nasojejunal tube placement, or inability to complete tube placement within 48 hours of onset;
  • Contraindications to enteral nutrition therapy or semi-recumbent positioning;
  • Pre-existing intellectual disability or physical disability affecting outcome assessment;
  • Gastrointestinal abnormalities likely to affect gastrointestinal function, such as short bowel syndrome (defined as total small bowel length ≤122 cm), ulcerative colitis, Crohn's disease, or any form of ostomy;
  • (BMI) \<18kg/m2;
  • Concomitant abdominal injury or extracranial injury with AIS score >3 in any region;
  • Presence of , severe cardiac insufficiency ( \<50%), severe hepatic failure ( score ≥7), or severe renal failure ( ≤30 mL/min or serum creatinine ≥4mg/dL) at NICU admission;
  • Concurrent severe disease with expected survival ≤14 days;
  • Pregnancy, within 30 days postpartum, or breastfeeding;
  • Refusal of treatment or receipt of palliative care;
  • Patient or family declines ;
  • Current participation in another interventional clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Patients will receive semi-elemental enteral nutrition.

    Dietary Supplement: Semi-elemental formula

  • Active comparator
    Control Group

    Patients will receive standard enteral nutrition.

    Dietary Supplement: Standard formula

Interventions

  • Dietary supplementSemi-elemental formula

    Treatment: Semi-elemental enteral nutrition Objective: To assess the efficacy of semi-elemental enteral nutrition in enhancing gastrointestinal tolerance in patients with severe traumatic brain injury.

  • Dietary supplementStandard formula

    Treatment: Standard enteral nutrition Objective: To serve as the control for evaluating the efficacy and safety of semi-elemental enteral nutrition versus standard nutritional therapy

06

What researchers measure

Primary outcomes

  1. Incidence of Gastrointestinal Intolerance

    Proportion of patients developing gastrointestinal intolerance within 7 days of enteral nutrition initiation. (Composite endpoint including: vomiting, diarrhea, constipation, gastroparesis, gastrointestinal bleeding, and abdominal distension.)

    Time frame: Within 7 days.

Secondary outcomes

  1. Hospitalization length of stay (LOS)

    Total length of stay in the hospital.

    Time frame: Periprocedural.

  2. NICU LOS

    Total length of stay in the neurological intensive care unit (NICU)

    Time frame: Periprocedural

  3. In-hospital mortality

    Mortality rate in hospital.

    Time frame: Periprocedural.

  4. ICU mortality

    Mortality rate in NICU

    Time frame: Periprocedural

  5. Three-month mortality

    Mortality rate at 3-month.

    Time frame: Within 3 months.

  6. Six-month mortality

    Mortality rate at 6-month.

    Time frame: Within 6 months.

  7. Functional outcomes (GOSE)

    The Glasgow Outcome Scale-Extended (GOSE) scores at 3 and 6 months. The score ranges from 1 to 8, with higher scores indicating a better outcome.

    Time frame: Within 6 months.

  8. Functional outcomes (Barthel)

    The Barthel Index scores at 3 and 6 months.The score ranges from 1 to 100, with higher scores indicating a better outcome.

    Time frame: Within 6 months.

  9. Gastrointestinal intolerance events

    Gastrointestinal intolerance events within 7 days of enteral nutrition initiation, including: 1. Incidence of diarrhea. 2. Diarrhea-free days. 3. Incidence of constipation. 4. Incidence of vomiting. 5. Incidence of gastroparesis. 6. Incidence of abdominal distension. 7. Time to first onset of symptoms. 8. Symptom duration.

    Time frame: Within 7 days.

  10. Infection

    Infection rate during 14-day period (or throughout hospitalization if discharged earlier).

    Time frame: Within 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Will be determined in accordance with sponsor requirements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 18 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Jul 29, 2025
StartActual
May 18, 2025
Primary completionEst.
Nov 18, 2026
CompletionEst.
May 31, 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07092423
Lead sponsor
Tang-Du Hospital
Collaborators
Ankang Central Hospital, Qilu Hospital of Shandong University (Qingdao), 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China, 904th Hospital of the Joint Logistics Support Force of the PLA, West China Hospital, Qianfoshan Hospital, The First Affiliated Hospital of Xinxiang Medical College, Hanzhong Central Hospital, The General Hospital of Western Theater Command, The General Hospital of Northern Theater Command, Tangshan Gongren Hospital, 987th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
May 18, 2025
Primary completion
Nov 18, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Haixiao Liu, MD, PhD
Contact
hai_xiao_liu@163.com
+86-029-84717556
Hao Guo, MD, PhD
Contact
guohao0622@163.com
+86-029-84717556
Yan Qu, MD, PhD
study chair · Tang-Du Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion